跳转至内容
Merck
所有图片(1)

Key Documents

124011

Sigma-Aldrich

Akt抑制剂IV

The Akt Inhibitor IV, also referenced under CAS 681281-88-9, controls the biological activity of Akt. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

别名:

Akt抑制剂IV

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C31H27IN4S
分子量:
614.54
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

solid

製造商/商標名

Calbiochem®

儲存條件

OK to freeze
desiccated (hygroscopic)
protect from light

顏色

yellow

溶解度

DMSO: 5 mg/mL

運輸包裝

ambient

儲存溫度

2-8°C

InChI

1S/C31H27N4S.HI/c1-3-34-28-22-23(31-32-26-16-10-11-17-29(26)36-31)18-19-27(28)35(25-14-8-5-9-15-25)30(34)20-21-33(2)24-12-6-4-7-13-24;/h4-22H,3H2,1-2H3;1H/q+1;/p-1

InChI 密鑰

NAYRELMNTQSBIN-UHFFFAOYSA-M

一般說明

一种细胞可渗透且可逆的苯并咪唑化合物,可能通过靶向Akt上游,PI3-K下游的激酶的ATP结合位点来抑制Akt磷酸化/激活。显示可阻断786-O细胞中Akt介导的FOXO1a核输出(IC50 = 625 nM)和细胞增殖(IC50<1.25 µM)。与基于磷脂酰肌醇类似物的Akt抑制剂(目录编号124005,124008,124009)不同,该抑制剂不影响PI3-K。
一种细胞可渗透且可逆的苯并咪唑化合物,通过靶向Akt上游,PI3-K下游的激酶的ATP结合位点来抑制Akt磷酸化/激活。显示可阻断786-O细胞中Akt介导的FOXO1a核输出(IC50 = 625 nM)和细胞增殖(IC50<1.25 M)。与基于磷脂酰肌醇类似物的Akt抑制剂(目录编号124005,124008,124009)不同,该抑制剂不影响PI3K。也可获得10 mM(1 mg/163 l)Akt抑制剂IV的DMSO溶液。

生化/生理作用

主靶
Akt
产物不与ATP竞争。
可逆性:是
细胞可渗透性:具有
靶标IC50:625 nM阻断Akt介导的FOXO1a核输出;<1.25 µM阻断786-O细胞中Akt介导的细胞增殖

包裝

用惰性气体包装

警告

毒性:标准处理(A)

重構

在复溶后,分装并冷冻保存(-20°C)。储备溶液在-20°C下可稳定保存至多6个月。

其他說明

Kau, T.R., et al. 2003.Cancer Cell4, 463.



Selected Citations
Lee, J., et al. 2009.Cell Stem Cell5, 76.


法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Bing Xu et al.
Frontiers in neuroscience, 14, 766-766 (2020-08-28)
Poor postoperative pain (POP) control increases perioperative morbidity, prolongs hospitalization days, and causes chronic pain. However, the specific mechanism(s) underlying POP is unclear and the identification of optimal perioperative treatment remains elusive. Akt and mammalian target of rapamycin (mTOR) are
Roshini Fernando et al.
Journal of immunology (Baltimore, Md. : 1950), 204(7), 1724-1735 (2020-02-23)
IL-23 and IL-12, two structurally related heterodimeric cytokines sharing a common subunit, divergently promote Th cell development and expansion. Both cytokines have been implicated in the pathogenesis of thyroid-associated ophthalmopathy (TAO), an autoimmune component of Graves disease. In TAO, CD34+
Yu-Ying Chao et al.
Journal of cellular physiology (2022-10-18)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers because of its late diagnosis and chemoresistance. Primary cilia, the cellular antennae, are observed in most human cells to maintain development and differentiation. Primary cilia are gradually lost during
Bin Li et al.
The Journal of clinical endocrinology and metabolism, 99(9), 3363-3372 (2014-05-21)
TSH provokes expression of inflammatory genes in CD34(+) fibrocytes. These cells appear to infiltrate the orbit in Graves' disease (GD), where they putatively become the CD34(+) orbital fibroblast subset (GD-OF). This may have importance in solving the pathogenesis of thyroid-associated

商品

AldeRed™ 588-A is a red fluorescent live cell probe that detects ALDH activity used to identify cancer stem cells and progenitor cells in culture. Cancer stem cells (CSCs) are subpopulations of cancer cells that can self-renew, generate diverse cells in the tumor mass, and sustain tumorigenesis. Some researchers believe that cancer arises from cancer stem cells that originate as a result of mutational hits on normal stem cells.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门